About this trial
The aim of this study is to describe the tumor microenvironment of solid tumors and to understand the changes induced by anti-cancer treatments, particularly those developed by Innate Pharma. Innate Pharma is a biotechnology company which discovers and develops therapeutic antibodies that exploit the innate immune system to improve cancer treatment. Thanks to this study, it will be possible to correlate clinical and immunological characteristics with the patient\'s clinical features. The analyses generated will contribute to the design and improvement of innovative therapeutic antibodies acting on the immune system
Eligibility criteria
Qualifiers
18 years of age or older
Histologic, cytologic or imaging confirmation of a malignancy in accordance with targeted indications
Written informed consent signed from subject prior to performing any protocol-related procedures
Disqualifiers
Use of any investigational agent within 14 days prior first visit;
Patient under guardianship/trusteeship or legally incapacitated person;
Patient unable to understand read and/or sign an informed consent;
Uncooperative or potentially non-compliant for the study or study procedures patient, or with foreseeable regular follow-up difficulties;
Trial design
Treatments tested in this trial
- blood collection
- tissue specimen collection